Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) CFO Raphi Levy sold 2,871 shares of the firm's stock in a transaction on Friday, August 21st. The shares were sold at an average price of $15.00, for a total value of $43,065.00. Following the completion of the sale, the chief financial officer directly owned 90,180 shares of the company's stock, valued at approximately $1,352,700. This trade represents a 3.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Raphi Levy also recently made the following trade(s):
- On Tuesday, August 11th, Raphi Levy sold 17,730 shares of Alpha Tau Medical stock. The stock was sold at an average price of $14.00, for a total transaction of $248,220.00.
- On Monday, July 6th, Raphi Levy sold 2,270 shares of Alpha Tau Medical stock. The shares were sold at an average price of $14.00, for a total transaction of $31,780.00.
- On Thursday, July 2nd, Raphi Levy sold 17,873 shares of Alpha Tau Medical stock. The shares were sold at an average price of $13.00, for a total transaction of $232,349.00.
- On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The shares were sold at an average price of $13.02, for a total transaction of $27,693.54.
- On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $12.00, for a total transaction of $240,000.00.
- On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total transaction of $220,000.00.
- On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $9.55, for a total transaction of $167,125.00.
- On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total transaction of $351,975.00.
Alpha Tau Medical Price Performance
DRTS stock opened at $14.70 on Wednesday. The firm has a 50 day moving average of $12.64 and a 200-day moving average of $9.73. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -14.13 and a beta of 1.17. The company has a current ratio of 11.09, a quick ratio of 7.79 and a debt-to-equity ratio of 0.15. Alpha Tau Medical Ltd. has a 12-month low of $3.18 and a 12-month high of $15.02.
Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.36). The company had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.14 million. As a group, equities analysts expect that Alpha Tau Medical Ltd. will post -0.92 EPS for the current fiscal year.
Hedge Funds Weigh In On Alpha Tau Medical
Institutional investors have recently made changes to their positions in the stock. Trifecta Capital Advisors LLC purchased a new stake in shares of Alpha Tau Medical in the fourth quarter valued at $48,000. Envestnet Asset Management Inc. purchased a new stake in Alpha Tau Medical during the 3rd quarter worth about $62,000. Bank of America Corp DE raised its stake in Alpha Tau Medical by 2,779.1% in the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company's stock valued at $101,000 after purchasing an additional 21,677 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Alpha Tau Medical by 291.7% in the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company's stock valued at $116,000 after purchasing an additional 17,500 shares in the last quarter. Finally, Everhart Financial Group Inc. purchased a new position in Alpha Tau Medical in the 2nd quarter valued at about $126,000. 2.65% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research analysts have recently weighed in on the company. HC Wainwright raised their price target on Alpha Tau Medical from $15.00 to $16.00 and gave the company a "buy" rating in a research report on Tuesday, August 11th. Benchmark reiterated a "buy" rating on shares of Alpha Tau Medical in a research report on Thursday, July 23rd. Zacks Research raised shares of Alpha Tau Medical from a "strong sell" rating to a "hold" rating in a research note on Monday, August 3rd. LADENBURG THALM/SH SH raised their target price on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the company a "buy" rating in a report on Tuesday, May 12th. Finally, Barclays upped their price target on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the company an "overweight" rating in a report on Thursday, June 4th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Alpha Tau Medical has a consensus rating of "Moderate Buy" and an average target price of $12.80.
Check Out Our Latest Stock Report on DRTS
Alpha Tau Medical Company Profile
(
Get Free Report)
Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.
The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
